S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

GenMark Diagnostics, Inc. (NASDAQ:GNMK) SVP Michael Gleeson Sells 1,432 Shares

Last updated on Thursday, February 25, 2021 | 2021 MarketBeat

GenMark Diagnostics, Inc. (NASDAQ:GNMK) SVP Michael Gleeson sold 1,432 shares of GenMark Diagnostics stock in a transaction on Tuesday, February 23rd. The stock was sold at an average price of $19.35, for a total transaction of $27,709.20. Following the transaction, the senior vice president now directly owns 412,956 shares of the company's stock, valued at approximately $7,990,698.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Gleeson also recently made the following trade(s):

  • On Friday, February 19th, Michael Gleeson sold 2,340 shares of GenMark Diagnostics stock. The stock was sold at an average price of $21.80, for a total transaction of $51,012.00.
  • On Monday, January 25th, Michael Gleeson sold 33,027 shares of GenMark Diagnostics stock. The stock was sold at an average price of $14.22, for a total transaction of $469,643.94.

GenMark Diagnostics stock traded down $0.49 during midday trading on Thursday, hitting $18.80. 1,100,321 shares of the stock were exchanged, compared to its average volume of 1,273,962. GenMark Diagnostics, Inc. has a 52-week low of $3.36 and a 52-week high of $23.59. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -46.24 and a beta of 3.02. The business's 50-day moving average price is $16.65 and its 200-day moving average price is $14.26. The company has a quick ratio of 3.84, a current ratio of 4.33 and a debt-to-equity ratio of 0.75.

Several equities research analysts have weighed in on GNMK shares. Zacks Investment Research downgraded shares of GenMark Diagnostics from a "buy" rating to a "hold" rating in a research note on Thursday, February 11th. Canaccord Genuity lifted their price target on shares of GenMark Diagnostics from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, February 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of "Buy" and a consensus price target of $19.60.

A number of institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its holdings in GenMark Diagnostics by 16.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,350 shares of the medical equipment provider's stock worth $93,000 after purchasing an additional 900 shares during the last quarter. Swiss National Bank raised its position in GenMark Diagnostics by 0.9% in the fourth quarter. Swiss National Bank now owns 144,600 shares of the medical equipment provider's stock worth $2,111,000 after acquiring an additional 1,300 shares during the period. Harbor Investment Advisory LLC raised its position in GenMark Diagnostics by 361.6% in the third quarter. Harbor Investment Advisory LLC now owns 1,731 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 1,356 shares during the period. Bank of New York Mellon Corp raised its position in GenMark Diagnostics by 0.5% in the fourth quarter. Bank of New York Mellon Corp now owns 270,673 shares of the medical equipment provider's stock worth $3,952,000 after acquiring an additional 1,426 shares during the period. Finally, JPMorgan Chase & Co. raised its position in GenMark Diagnostics by 5.9% in the third quarter. JPMorgan Chase & Co. now owns 25,961 shares of the medical equipment provider's stock worth $363,000 after acquiring an additional 1,443 shares during the period. Institutional investors and hedge funds own 96.94% of the company's stock.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: Dividend Kings

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Cloud Computing Stocks to Lift Your Portfolio to New Heights

Cloud computing sounds complicated, and it has become more sophisticated as it evolves. However, the basic idea behind the cloud is the same. The “cloud” is a euphemistic term for the delivery of different services via the internet. In its early days, the cloud was used exclusively for data storage. Here’s an easy example of why this was important.

Back when the internet was cutting its teeth, I worked in marketing communications. The need to comply with Total Quality Control Systems (TQCS) for our largest clients meant we had to save every version of our files. Every. Single. One. Now imagine that you’re producing a 120-page product catalog complete with photos and charts. Your hard drive is burning up just thinking about it. Yet that “data” had to be stored somewhere. And so we had a virtual server farm to try to warehouse all these graphic intensive (and memory sucking) files until we could archive them.

Other than the storage nightmare, consider that it was a pain to work remotely. You could copy a file from the server, but then were you working on the right file? I’m sure at least one person is reading this who remembers this pain.

The cloud takes that away. Cloud computing allows you to store files on a secure, remote server that everyone can access anywhere they have an internet connection. But it’s become so much more than that. Cloud computing now gives businesses a platform from which they can create applications and software. If that sounds confusing, I hope to simplify it in this presentation. To help you understand which cloud computing stocks, you may want to add to your portfolio, and we’ve created this special presentation. These are seven of the cloud computing stocks that will continue to grow with the sector.

View the "7 Cloud Computing Stocks to Lift Your Portfolio to New Heights".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.